Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Total Liabilities (2016 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Total Liabilities for 15 consecutive years, with $53.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Liabilities fell 16.13% year-over-year to $53.8 million, compared with a TTM value of $53.8 million through Sep 2025, down 16.13%, and an annual FY2024 reading of $50.8 million, up 32.04% over the prior year.
  • Total Liabilities was $53.8 million for Q3 2025 at Fennec Pharmaceuticals, up from $52.3 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $66.2 million in Q1 2024 and bottomed at $2.9 million in Q1 2021.
  • Average Total Liabilities over 5 years is $34.3 million, with a median of $29.5 million recorded in 2022.
  • The sharpest move saw Total Liabilities skyrocketed 340.15% in 2023, then dropped 21.0% in 2025.
  • Year by year, Total Liabilities stood at $7.0 million in 2021, then skyrocketed by 321.48% to $29.5 million in 2022, then skyrocketed by 30.43% to $38.5 million in 2023, then soared by 32.04% to $50.8 million in 2024, then rose by 5.78% to $53.8 million in 2025.
  • Business Quant data shows Total Liabilities for FENC at $53.8 million in Q3 2025, $52.3 million in Q2 2025, and $52.3 million in Q1 2025.